13 -14
May

Venture Capital & Private Equity

Investment Challenges and Opportunities in Emerging Biotech Markets

Hard Rock Hotel San Diego

What to expect

Timely information, interactive format

Real insights are shared in conversations, not lectures. That’s why our unique roundtable format guarantees real learning and ensures you only attend discussions that deliver value to you. rnrnJoin as many as four roundtable discussions, each with up to 20 other subject experts, networking with top-level peers in an informal, relaxed and sociable environment.

Featuring Industry Leaders and Decision Makers

Our Facilitators

Andrea Small-Howard

President GB Sciences

Devin Swanson

Director, External Innovation Johnson & Johnson Innovative Medicines

David Crean

Managing Partner & Partner Cardiff Advisory LLC & 1004 Venture Partners

George Ng

Chief Executive Officer Processa Pharmaceuticals

George Ng is a seasoned executive and entrepreneur in the life sciences industry, currently serving as Chief Executive Officer and Board Director at Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) and as a partner at PENG Life Science Ventures (PENG LSV). Previously, he was President, COO, and Board Director at Calidi Biotherapeutics, Inc. (NYSE: CLDI), where he led the company’s successful public listing.
Mr. Ng co-founded Scilex Pharmaceuticals, Inc. (NASDAQ: SCLX), guiding it through product development, clinical trials, FDA approval, $140 million in financing, and its commercial launch and sale. His leadership career also includes senior executive roles at Sorrento Therapeutics, BioDelivery Sciences, Spectrum Pharmaceuticals, and Alpharma (now part of Pfizer), contributing to multiple successful drug product launches.
Before entering industry, Mr. Ng was a partner at two Am Law 200 firms, where he founded and led a national life sciences practice. He has served on the boards of several biotech companies and is a frequent speaker on legal, regulatory, and business topics.
Mr. Ng holds a Juris Doctor from the University of Notre Dame School of Law and a B.A.S. in Biochemistry and Economics from the University of California, Davis.

Mehran Moghaddam

CEO OROX Biosciences, Inc.

Susan Whitehead

Board Director PACT Pharma

Our Past Facilitators

Anthony Maida

Chief Clinical Officer – Translational Medicine Oncotelic Therapeutics, Inc.

Dr. Maida is currently Chief Clinical Officer – Translational Medicine for Oncotelic, Inc. focused on the immunotherapy of cancer and infectious disease.  Formerly he was Senior Vice President – Clinical Research for Northwest Biotherapeutics, Inc., a cancer vaccine company focused on therapy of patients with glioblastoma multiforme and prostate cancer.  He is responsible for the oversight of the clinical and scientific operations of Oncotelic Therapeutics, Inc.  Dr. Maida was formerly Vice President of Clinical Research and General Manager, Oncology, World-wide for PharmaNet, Inc.  Prior to coming to Pharmanet Dr. Maida served as Chairman, Founder and Director of BioConsul Drug Development Corporation and Principal of Anthony Maida Consulting International, servicing pharmaceutical firms, venture capital, hedge funds and Wall Street, in the clinical development of therapeutic products and product/company acquisitions. For 30 years, Dr. Maida has focused on the clinical development of immunotherapies to treat patients with cancer.  Dr. Maida’s skill set includes the execution and oversight of finance, operations, research, and commercial clinical and scientific development, regulatory and manufacturing for the development of various therapeutic modalities.  Dr. Maida has served in a number of executive roles, including, Chairman, CEO, COO, CSO, CFO and business development.  Dr. Maida serves or has served on the advisory board of EndPoint BioCapital, Sdn Bhd (Kuala Lumpur, Malaysia), and as an advisor, consultant and technical analyst for CMX Capital, LLC, Sagamore Bioventures, Roaring Fork Capital, Toucan Capital, North Sound Capital, The Bonnie J. Addario Lung Cancer Foundation and Pediatric BioScience, Inc.  Additionally, Dr. Maida has been retained by Abraxis BioScience, Inc., Northwest BioTherapeutics, Inc. and Takeda Chemical Industries, Ltd. (Osaka, Japan). Dr. Maida sat on multiple public company boards and advisory committees.  Dr. Maida holds a B.A. degree in Biology, a B.A. Degree in History, a MBA, a MA in toxicology and a Ph.D. in Immunology.  He is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the Society of Neuro-Oncology (SNO), the International Society for Biological Therapy of Cancer (iSBTc) and the American Chemical Society.  Dr. Maida holds a number of patents and patent applications associated with various therapeutic modalities and approaches.